Ahava Medical and Rehabilitation Center, LLC
Ahava Medical and Rehabilitation Center, LLC was paid $152.08M by Medicaid between Jan 2018 and Dec 2024, across 319 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 15% of everything it billed.
33Billing provider infoAHAVA MEDICAL AND REHABILITATION CENTER, LLC
BROOKLYN, NY 11210
BROOKLYN, NY 11210
33aNPI1184878274assigned 11/17/2008
33bProvider typeRehabilitation Practitioner
28Total paid$152.08M
24GClaims1,780,252
24DCodes billed319
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Practitioner providers in New York
Rank by total paid#1 of 18
Median peer was paid$68K
This provider vs. median2,221×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 193,216 | $15.44M | |
| 2019 | 241,014 | $19.69M | |
| 2020 | 281,709 | $22.90M | |
| 2021 | 167,500 | $16.02M | |
| 2022 | 234,596 | $19.85M | |
| 2023 | 279,587 | $25.95M | |
| 2024incomplete | 382,630 | $32.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 195,263 | 141,417 | $22.05M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 10% | 181,828 | 19,005 | $15.86M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 8.2% | 104,713 | 76,851 | $12.50M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.9% | 182,730 | 40,764 | $10.46M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 5.3% | 59,062 | 57,798 | $8.03M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.4% | 105,147 | 24,181 | $6.70M |
| 97113 | 3.9% | 62,311 | 14,815 | $5.97M | |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.6% | 54,249 | 15,069 | $5.54M |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 2.6% | 29,411 | 9,618 | $3.91M |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 2.3% | 1,073 | 1,045 | $3.55M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 71,722 | 21,621 | $3.26M |
| 97116 | 1.9% | 62,785 | 17,660 | $2.94M |
307 more codes
| 76000 | 1.9% | 12,358 | $2.86M | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.7% | 46,523 | $2.55M |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.6% | 23,414 | $2.51M |
| 92523 | 1.5% | 21,168 | $2.25M | |
| 0101T | 1.3% | 6,005 | $2.01M | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.1% | 19,283 | $1.69M |
| 97163 | 1.1% | 11,883 | $1.66M | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 1.1% | 12,335 | $1.66M |
| 97164 | 1.0% | 19,335 | $1.57M | |
| 76942 | 1.0% | 10,101 | $1.55M | |
| 20552 | <1% | 7,563 | $1.38M | |
| 97167 | <1% | 9,026 | $1.22M | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 19,228 | $1.15M |
| 20611 | <1% | 2,847 | $1.08M | |
| 97168 | <1% | 11,849 | $974K | |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 15,366 | $949K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 19,792 | $927K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 6,938 | $906K |
| 92250 | <1% | 9,768 | $853K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 5,976 | $800K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,884 | $786K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 4,086 | $768K |
| 93880 | <1% | 2,360 | $763K | |
| 93976 | <1% | 1,718 | $688K | |
| 92060 | <1% | 8,178 | $638K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,913 | $621K |
| G0295 | Electromagnetic therapy, to one or more areas, for wound care other than described in g0329 or for other uses | <1% | 3,388 | $609K |
| G0281 | Electrical stimulation, (unattended), to one or more areas, for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as part of a therapy plan of care | <1% | 4,343 | $597K |
| 92310 | <1% | 2,846 | $596K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 16,295 | $559K |
| V2020 | Frames, purchases | <1% | 10,005 | $550K |
| S9083 | Global fee urgent care centers | <1% | 10,496 | $524K |
| 25600 | <1% | 1,221 | $517K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,665 | $514K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,893 | $497K |
| 99000 | <1% | 26,414 | $482K | |
| 96415 | <1% | 721 | $379K | |
| 99441 | <1% | 2,827 | $358K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,064 | $344K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 8,744 | $343K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,527 | $335K |
| 11901 | <1% | 1,197 | $317K | |
| 92285 | <1% | 5,713 | $316K | |
| 17110 | <1% | 1,064 | $298K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,230 | $290K |
| 20553 | <1% | 1,436 | $288K | |
| 28470 | <1% | 600 | $276K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,607 | $270K |
| 96367 | <1% | 1,566 | $250K | |
| 97166 | <1% | 2,008 | $222K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 2,167 | $201K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,232 | $197K |
| 99051 | <1% | 15,420 | $189K | |
| 99401 | <1% | 4,765 | $178K | |
| 20550 | <1% | 772 | $172K | |
| 51798 | <1% | 918 | $172K | |
| V2784 | Lens, polycarbonate or equal, any index, per lens | <1% | 17,594 | $170K |
| D2750 | <1% | 450 | $154K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,007 | $141K |
| 99442 | <1% | 1,065 | $141K | |
| 97533 | <1% | 1,827 | $139K | |
| 93925 | <1% | 336 | $123K | |
| 94644 | <1% | 4,592 | $109K | |
| 93886 | <1% | 232 | $109K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,568 | $108K |
| 95886 | <1% | 1,041 | $108K | |
| 26720 | <1% | 239 | $107K | |
| 93978 | <1% | 266 | $106K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 961 | $103K |
| 10061 | <1% | 363 | $99K | |
| 10040 | <1% | 352 | $97K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 5,542 | $95K |
| 92065 | <1% | 17,321 | $92K | |
| 96136 | <1% | 700 | $92K | |
| 92201 | <1% | 1,064 | $86K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,787 | $86K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,544 | $86K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 414 | $86K |
| 76770 | <1% | 251 | $85K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 840 | $84K |
| D1110 | Prophylaxis - adult | <1% | 2,348 | $83K |
| G0445 | High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes | <1% | 820 | $81K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 715 | $68K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 2,449 | $65K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,939 | $64K |
| 11900 | <1% | 252 | $64K | |
| 92202 | <1% | 1,323 | $62K | |
| 93970 | <1% | 134 | $62K | |
| 11056 | <1% | 208 | $62K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,383 | $59K |
| 96130 | <1% | 823 | $58K | |
| 96417 | <1% | 555 | $57K | |
| 96416 | <1% | 155 | $55K | |
| 97124 | <1% | 1,932 | $54K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,858 | $52K |
| 97162 | <1% | 449 | $52K | |
| 20610 | <1% | 265 | $51K | |
| 29700 | <1% | 201 | $49K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,535 | $47K |
| 92083 | <1% | 646 | $47K | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 1,133 | $46K |
| 92341 | <1% | 1,150 | $45K | |
| V2203 | Spherocylinder, bifocal, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 834 | $45K |
| 96137 | <1% | 753 | $44K | |
| 92015 | Determination of refractive state | <1% | 10,214 | $43K |
| 10060 | <1% | 143 | $42K | |
| 90746 | <1% | 1,754 | $42K | |
| 11750 | <1% | 73 | $41K | |
| 97161 | <1% | 417 | $41K | |
| 99385 | <1% | 767 | $41K | |
| 93975 | <1% | 95 | $40K | |
| 99443 | <1% | 309 | $39K | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 1,426 | $38K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,273 | $36K |
| 51741 | <1% | 316 | $35K | |
| 27750 | <1% | 72 | $35K | |
| 92133 | <1% | 426 | $33K | |
| 27786 | <1% | 69 | $32K | |
| 94667 | <1% | 4,692 | $30K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,405 | $30K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 875 | $29K |
| 99050 | <1% | 3,195 | $29K | |
| V2303 | Spherocylinder, trifocal, plano to plus or minus 4.00d sphere, .12-2.00d cylinder, per lens | <1% | 467 | $28K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 2,991 | $28K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 2,265 | $27K |
| 11721 | <1% | 353 | $26K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,343 | $25K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 1,376 | $25K |
| 94200 | <1% | 4,559 | $24K | |
| V2300 | Sphere, trifocal, plano to plus or minus 4.00d, per lens | <1% | 410 | $23K |
| 99406 | <1% | 608 | $22K | |
| 90715 | <1% | 989 | $22K | |
| 99382 | <1% | 195 | $21K | |
| 11102 | <1% | 42 | $21K | |
| D0330 | Panoramic radiographic image | <1% | 733 | $21K |
| D0274 | Bitewings - four radiographic images | <1% | 1,060 | $21K |
| 95816 | <1% | 120 | $21K | |
| 99383 | <1% | 233 | $20K | |
| D0120 | Dental checkup, returning patient | <1% | 923 | $20K |
| 99386 | <1% | 360 | $19K | |
| 90686 | <1% | 874 | $18K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 1,694 | $17K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,715 | $17K |
| 94060 | <1% | 64 | $17K | |
| 96132 | <1% | 442 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,973 | $16K |
| 99407 | <1% | 441 | $16K | |
| 99384 | <1% | 177 | $16K | |
| D2954 | <1% | 160 | $15K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 283 | $15K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 105 | $14K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 747 | $14K |
| 11730 | <1% | 170 | $14K | |
| V2200 | Sphere, bifocal, plano to plus or minus 4.00d, per lens | <1% | 271 | $14K |
| 98926 | <1% | 694 | $14K | |
| S0395 | Impression casting of a foot performed by a practitioner other than the manufacturer of the orthotic | <1% | 75 | $13K |
| 29075 | <1% | 51 | $13K | |
| 93000 | <1% | 3,658 | $13K | |
| 96112 | <1% | 83 | $13K | |
| 92558 | <1% | 280 | $13K | |
| 99381 | <1% | 103 | $12K | |
| 10120 | <1% | 43 | $12K | |
| 29130 | <1% | 59 | $12K | |
| 26600 | <1% | 25 | $11K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 1,662 | $11K |
| 90707 | <1% | 513 | $11K | |
| 90688 | <1% | 585 | $10K | |
| 29280 | <1% | 42 | $8K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 63 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,815 | $8K |
| 95912 | <1% | 121 | $7K | |
| 95911 | <1% | 155 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 351 | $7K |
| 93890 | <1% | 159 | $7K | |
| 90677 | <1% | 258 | $7K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,548 | $7K |
| 96160 | <1% | 165 | $6K | |
| 90756 | <1% | 264 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,783 | $6K |
| 96113 | <1% | 83 | $6K | |
| 29540 | <1% | 41 | $6K | |
| 25605 | <1% | 12 | $6K | |
| 90836 | <1% | 58 | $6K | |
| 29705 | <1% | 23 | $5K | |
| 76775 | <1% | 57 | $5K | |
| 96131 | <1% | 294 | $5K | |
| 90674 | <1% | 210 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 44 | $5K |
| 90710 | <1% | 216 | $5K | |
| 11055 | <1% | 16 | $5K | |
| 96101 | <1% | 13 | $4K | |
| 90723 | <1% | 189 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,061 | $4K |
| 90656 | <1% | 356 | $4K | |
| V2100 | Sphere, single vision, plano to plus or minus 4.00, per lens | <1% | 966 | $4K |
| 64454 | <1% | 13 | $4K | |
| 90632 | <1% | 184 | $4K | |
| 29065 | <1% | 14 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,558 | $3K |
| 0011A | <1% | 255 | $3K | |
| 92225 | <1% | 78 | $3K | |
| 90633 | <1% | 149 | $3K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 163 | $3K |
| 20600 | <1% | 12 | $3K | |
| H0049 | Alcohol and/or drug screening | <1% | 57 | $3K |
| 29125 | <1% | 32 | $2K | |
| 0012A | <1% | 140 | $2K | |
| 90697 | <1% | 87 | $2K | |
| 69209 | <1% | 14 | $2K | |
| 73110 | <1% | 319 | $2K | |
| 90700 | <1% | 87 | $2K | |
| 91322 | <1% | 27 | $2K | |
| 97165 | <1% | 20 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 15 | $2K |
| 90716 | <1% | 58 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 265 | $2K |
| 87631 | <1% | 37 | $2K | |
| 97760 | <1% | 51 | $2K | |
| 99201 | <1% | 13 | $2K | |
| 99001 | <1% | 145 | $2K | |
| 90750 | <1% | 13 | $2K | |
| 90658 | <1% | 159 | $2K | |
| 87428 | <1% | 77 | $2K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 567 | $1K |
| 0013A | <1% | 111 | $1K | |
| 87077 | <1% | 1,681 | $1K | |
| 90734 | <1% | 95 | $1K | |
| 90696 | <1% | 61 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 116 | $1K |
| 90461 | <1% | 561 | $1K | |
| 81025 | <1% | 392 | $1K | |
| 90619 | <1% | 41 | $1K | |
| 0001A | <1% | 43 | $866.04 | |
| 90732 | <1% | 29 | $865.05 | |
| 99024 | <1% | 87 | $840.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,189 | $836.90 |
| 81003 | <1% | 509 | $747.10 | |
| 97026 | <1% | 36 | $724.63 | |
| 94668 | <1% | 92 | $697.69 | |
| 73630 | <1% | 225 | $685.01 | |
| 73130 | <1% | 89 | $684.82 | |
| 99402 | <1% | 14 | $680.63 | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 148 | $636.22 |
| 86580 | <1% | 28 | $600.97 | |
| 0552T | <1% | 228 | $594.82 | |
| 82962 | <1% | 1,037 | $583.30 | |
| 97010 | <1% | 103 | $561.85 | |
| 87807 | <1% | 15 | $541.00 | |
| 81005 | <1% | 169 | $464.56 | |
| 91301 | <1% | 508 | $460.08 | |
| 36592 | <1% | 15 | $442.19 | |
| 0031A | <1% | 53 | $427.34 | |
| 90649 | <1% | 25 | $422.86 | |
| 73600 | <1% | 141 | $418.21 | |
| 90685 | <1% | 17 | $415.40 | |
| 83655 | <1% | 30 | $411.41 | |
| 90713 | <1% | 17 | $392.92 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12 | $373.68 |
| 92226 | <1% | 14 | $294.99 | |
| 91300 | <1% | 35 | $273.77 | |
| 90480 | <1% | 25 | $272.00 | |
| J3490 | Unclassified drugs | <1% | 571 | $257.24 |
| 90648 | <1% | 12 | $250.43 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,478 | $231.76 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,917 | $227.46 |
| 90672 | <1% | 13 | $218.03 | |
| 81000 | <1% | 343 | $163.51 | |
| 87070 | <1% | 1,136 | $138.54 | |
| 91320 | <1% | 14 | $131.10 | |
| 81002 | <1% | 971 | $112.67 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 835 | $106.40 |
| 96127 | <1% | 580 | $97.15 | |
| 86318 | <1% | 131 | $90.20 | |
| 73080 | <1% | 26 | $65.42 | |
| 99072 | <1% | 281 | $35.00 | |
| 87430 | <1% | 132 | $30.32 | |
| 94760 | <1% | 1,265 | $26.45 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 680 | $25.57 |
| 73100 | <1% | 14 | $18.00 | |
| 85018 | <1% | 65 | $15.92 | |
| 86769 | <1% | 13 | $15.91 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 101 | $7.39 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 823 | $3.93 |
| 81001 | <1% | 35 | $2.33 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 508 | $1.10 |
| 3008F | <1% | 778 | $0.70 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 714 | $0.36 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 47 | $0.02 |
| 3078F | 0% | 200 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 147 | $0.00 |
| 90653 | 0% | 56 | $0.00 | |
| 99080 | 0% | 540 | $0.00 | |
| 90863 | 0% | 39 | $0.00 | |
| 3077F | 0% | 52 | $0.00 | |
| 69210 | 0% | 12 | $0.00 | |
| 3210F | 0% | 44 | $0.00 | |
| 3079F | 0% | 107 | $0.00 | |
| 3044F | 0% | 127 | $0.00 | |
| 93892 | 0% | 13 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 131 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 14 | $0.00 |
| 3074F | 0% | 145 | $0.00 | |
| 91303 | 0% | 44 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 27 | $0.00 |
| 3294F | 0% | 14 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 14 | $0.00 |
| 3075F | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEBOVITS, GEORGE (OWNER)